Want to track PRTA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 64 days
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
Zacks | 1 year ago
2025 © Marketlog. All Rights Reserved.
